Jonathan Rosenberg, MD
Gastroenterology · New York, NYNPI 1578556908
Payments from drug & device makers
Across 21 payments — averaging $9029.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$137K
- Teva Pharmaceuticals USA, Inc.$50K
- EMD Serono, Inc.$3K
- Pfizer$198
- Sanofi$55
- Capsovision, Inc.$43
- plus $41 from 2 others
Across 14 payments — averaging $526.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$7K
What the payments were for
- Consulting fees$3,00090%
- Food & beverage$32410%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 5 | $136,719 |
| Teva Pharmaceuticals USA, Inc. | 6 | $49,556 |
| EMD Serono, Inc. | 1 | $3,000 |
| Pfizer | 3 | $198 |
| Sanofi | 2 | $55 |
| Capsovision, Inc. | 2 | $43 |
| AstraZeneca | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$189,612 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 53 | $46,315 |
| Dexlansoprazole DrDexlansoprazole | 93 | $29,782 |
| Mesalamine | 39 | $25,935 |
| Mesalamine ErMesalamine | 23 | $10,827 |
| Famotidine | 401 | $6,270 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 70 | $4,472 |
| Pantoprazole Sodium | 271 | $4,436 |
| Omeprazole | 313 | $3,770 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 187 | $2,460 |
| Budesonide DrBudesonide | 19 | $1,868 |
| Lubiprostone | 17 | $1,590 |
| Rabeprazole Sodium | 46 | $1,241 |
| Lansoprazole | 59 | $1,109 |
| Esomeprazole Magnesium | 22 | $771 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 26 | $457 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New York
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- Ira JacobsonNew York$1.8M
- James MarionNew York$1.7M
- Jean Frederick ColombelNew York$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.